Comparative Efficacy of Omeprazole plus Mosapride Combination Therapy versus Omeprazole Monotherapy in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease: a randomized controlled trial

Phase 4

Completed

• Conditions: proton pump inhibitor refractory gastroesophageal reflux disease; mosapride; proton pump inhibitor; gastroesophageal reflux disease; combined therapy

• Registration Number: TCTR20190418003
• Lead Sponsor: Rajavithi Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2018-01-01
• Study Start: 2019-04-18
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

the patients who experienced a symptom of heartburn and/or regurgitation more than twice weekly unresponsive to at least 8 weeks of a standard dose of proton pump inhibitor, defined by having the frequency scale for symptoms of gastroesophageal reflux disease total score of eight points or more

Exclusion Criteria

(i) who had a previous history of esophageal or gastrointestinal surgery except appendectomy and cholecystectomy (ii) who had severe cardiac or pulmonary disease, renal failure, liver cirrhosis and severe systemic illness (iii) who had an active Helicobacter pylori infection, determined by both the rapid urease test and histological identification, or upper gastrointestinal diseases such as malignancy or peptic ulcers (iv) who was in a state of pregnancy or lactating woman (v) who were hypersensitivity or allergy to mosapride or omeprazole

Study & Design

• Study Type: Interventional
• Study Design: Not specified